LSD1 inhibitors

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or formula (II):

• or a pharmaceutically acceptable salt thereof:
• wherein:
• R1 is hydrogen, C1-C4 alkyl or C1-C4 acyl;
• L is —(CH2)s—CR2R3—(CH2)n—;
• R2 and R3 are each independently hydrogen, C1-C4 alkyl, —OR4 or aralkyl;
• each R4 is independently hydrogen or C1-C4 alkyl;
• X is —W—R5 or Y—R6;
• W is —NR4— or —O—;
• Y is —C(O)—, —S—, —SO—, —SO2—, —NR4SO2—, —SO2NR4— or —NR4C(O)—;
• R5 is acyl, C1-C4 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of said cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally independently substituted with one or more R8;
• R6 is C1-C6 alkyl, aryl, —NR4R7 or heterocyclyl optionally independently substituted on one or more carbon atoms with C1-C6 alkyl, halogen, cyano, haloalkyl or optionally independently substituted on one or more nitrogen atom with —C(O)C1-C6alkyl;
• —C(O)OC1-C6 alkyl;
• —C(O)NR4C1-C6alkyl, or —S(O)2NR4C1-C6 alkyl;
• R7 is hydroxyl, alkoxy, —SO2C1-C6alkyl;
• —SO2cycloalkyl, or —SO2aryl, wherein the cycloalkyl or aryl of each of the —SO2cycloalkyl and —SO2aryl is optionally independently substituted with one or more R8;
• each R8 is halogen, hydroxyl, amino, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, haloalkyl, alkoxy, alkylamino, dialkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl, —(CH2)nCOOR4, —(CH2)nC(O)NR4OC1-C6alkyl;
• —(CH2)nC(O)NR4SO2C1-C6alkyl, —(CH2)nC(O)NR4SO2cycloalkyl, —(CH2)nC(O)NR4SO2aryl, —C2-C6 alkenylC(O)OR4, —C2-C6 alkenylC(O)NR4SO2C1-C4 alkyl, or —C2-C6 alkenylC(O) NR4SO2aryl, wherein each of the cycloalkyl, aryl, heteroaryl, heterocyclyl is optionally independently substituted with one or more C1-C3 alkyl or —CH2NR4SO2aryl;
• m is 0 or 1;
• s is 0 or 1;
• each n is 0, 1, or 2;
• each p is 0, 1 or 2;
• each RA group is independently oxo or C1-C3 alkyl, or two RA groups on different ring atoms together form a C1-C3 bridge in which one of the bridge carbons is optionally replaced with —NH—;
• and
• each Q1, Q2 and Q3 is independently hydrogen, halogen, haloalkyl, C1-C4-alkyl, or C1-C4-alkoxy,
• wherein the cancer is Lung, or Hematologic cancer.